How PSMA Imaging and Therapy are Changing Care for Prostate Cancer Patients

Organized by the SNMMI Outreach Domain:
Satellite Breakfast Symposium in conjunction with the American Urological Association Annual Meeting.

Date: May 5, 2024
Location: Room 217A, Henry B. Gonzalez Convention Center, San Antonio, TX
Fee: Complimentary

7:30 am - Doors Open/Breakfast Served
8:00-9:30am - Educational Program

SNMMI has applied for 1.5 CME credit hours for this program.

Session Description: 

Several new radiopharmaceuticals are now being used in both large academic and small practice settings to stage and identify local and metastatic prostate cancer, including Ga-68 PSMA-11, 18F-DCFPyL, and flotufolastat F 18. In addition, the FDA in March 2022 approved Lu 177 vipivotide tetraxetan to treat PSMA-positive metastatic castration-resistant prostate cancer. 

In this session, co-presented by a nuclear medicine physician and a urologist, we will discuss the principles of PET imaging and review the results from key trials of PSMA-targeted PET imaging and therapy. We will describe important clinical scenarios in which PSMA-targeted PET imaging is indicated, with a focus on initial cancer staging, biochemical recurrence, management of oligometastatic disease, and selection of candidates for PSMA-targeted radioligand therapy. Additionally, we will review how one can start programs in PSMA-targeted PET imaging and radioligand therapy.

Attendees should be able to return to their practices with the knowledge necessary to start ordering PSMA PET scans and to discuss test results with patients. Additionally, urologists should be able to discuss radioligand therapy with their patients and where this novel therapy fits in the current treatment paradigm for men with castration-resistant prostate cancer.

Participants will be eligible to receive one (1.5) AMA-PRA Category 1 Credit and a certificate of participation from the Society of Nuclear Medicine and Molecular Imaging.

Learning Objectives:

  1. Understand the fundamentals of PET imaging agents and image acquisition, and how those factors play into the choice of radiotracer for imaging of prostate cancer.
  2. Recall the key findings regarding sensitivity and specificity of PSMA PET imaging in common clinical scenarios
  3. Recognize the appropriate clinical indications for PSMA imaging and therapy.


Frankis Almaguel, MD, PhD (moderator)
Director, Molecular Imaging and Therapeutics Program
Loma Linda University Cancer Center

Gary Ulaner, MD, PhD
Muzzy Chair of Molecular Imaging & Therapy
Hoag Family Cancer Institute
and Professor of Radiology
University of Southern California

Michael Gorin, MD
Associate Professor of Urology
Icahn School of Medicine at Mount Sinai

This Satellite Breakfast Symposium has been developed by the SNMMI and is supported by an educational grant from Lantheus Medical Imaging.

CE Accreditation

 CME Accreditation – AMA PRA Credits

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

SNMMI has applied for 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. To receive CE credit, learners must complete the online assessment and evaluation available after the program.